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Abstract
Background: Identification of predictive molecular alterations in lung adenocarcinoma is essential for accurate
therapeutic decisions. Although several molecular approaches are available, a number of issues, including tumor
heterogeneity, frequent material scarcity, and the large number of loci to be investigated, must be taken into
account in selecting the most appropriate technique. MALDI-TOF mass spectrometry (MS), which allows multiplexed
genotyping, has been adopted in routine diagnostics as a sensitive, reliable, fast, and cost-effective method. Our aim
was to test the reliability of this approach in detecting targetable mutations in non-small cell lung cancer (NSCLC). In
addition, we also analyzed low-quality samples, such as cytologic specimens, that often, are the unique source of
starting material in lung cancer cases, to test the sensitivity of the system.
Methods: We designed a MS–based assay for testing 158 mutations in the EGFR, KRAS, BRAF, ALK, PIK3CA, ERBB2, DDR2,
AKT, and MEK1 genes and applied it to 92 NSCLC specimens and 13 liquid biopsies from another subset of NSCLC
patients. We also tested the sensitivity of the method to distinguish low represented mutations using serial dilutions of
mutated DNA.
Results: Our panel is able to detect the most common NSCLC mutations and the frequency of the mutations observed in
our cohort was comparable to literature data. The assay identifies mutated alleles at frequencies of 2.5–10%. In addition, we
found that the amount of DNA template was irrelevant to efficiently uncover mutated alleles present at high frequency.
However, when using less than 10 ng of DNA, the assay can detect mutations present in at least 10% of the alleles.
Finally, using MS and a commercial kit for RT-PCR we tested liquid biopsy from 13 patients with identified mutations in
cancers and detected the mutations in 4 (MS) and in 5 samples (RT-PCR).
Conclusions: MS is a powerful method for the routine predictive tests of lung cancer also using low quality and scant
tissues. Finally, after appropriate validation and improvement, MS could represent a promising and cost-effective strategy
for monitoring the presence and percentage of the mutations also in non-invasive sampling.
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Background
Lung cancer is the leading cause of cancer death world-
wide. Non-small cell lung cancers (NSCLCs), primarily
adenocarcinoma (ADC) and squamous cell carcinoma
(SCC), account for approximately 80% of lung cancer
cases [1].
With the introduction of the Epidermal Growth Factor
Receptor/Tyrosine Kinase inhibitors (EGFR-TKIs), which
target cancer cells harboring activating EGFR mutations,
the detection of somatic mutations became relevant to
treatment choices for lung ADC [2]. Erlotinib, gefitinib,
and afatinib are used to target EGFR-activating mutations.
More recently, the new drug osimertinib was introduced.
This molecule can inhibit EGFR kinase activity in the
presence of the EGFR T790 M mutation, which confers
resistance to the other inhibitors [3–6]. Yet another drug,
crizotinib, inhibits ALK, ROS1, and MET when their
kinase activities are aberrantly activated [7–10].
Ongoing clinical trials are investigating emerging agents
capable of avoiding acquired tumor resistance to the com-
mon TKIs, or of targeting other activated proteins, such
as PI3K, AKT1, ERBB2, MEK1, and DDR2 [10, 11].
Mutations in KRAS (found in 25–40% of ADC) are a
negative prognostic biomarker for NSCLC, since no
drugs have been developed to inhibit the mutant protein.
Alternative strategies, such as inhibition of MEK, have
been suggested as treatment for patients with KRAS-mu-
tated cancers [12].
The most frequent activating mutations in lung ADC,
other than KRAS, involve EGFR (15%), whereas BRAF,
ERBB2, and MEK1 are mutated in less than 2% of cases.
PIK3CA mutations are present in approximately 1–3%
of NSCLCs, and are more common in SCCs (15%).
DDR2 mutations are present in 2% of SCCs. ALK and
ROS1 translocations and MET amplifications are typical
of ADCs, representing 5%, 4%, and 2% of cases, respect-
ively. AKT1 mutations are found in 1% of lung cancers,
more frequently in SCCs [10, 11].
A list of druggable molecular markers and pathways in
lung cancer is provided in Fig. 1.
Based on the growing knowledge of inhibitors that
target abnormally activated kinases and the resultant
clinical inclusion of new drugs, the optimal choice of
treatment of NSCLC patients relies critically on
screening the tumor-related genetic alterations.
Different issues should be taken into account for
the molecular characterization of NSCLC. First,
NSCLC are heterogeneous and cells harboring a
specific mutation may represent a minor clone in a
mixture of neoplastic cells, as well as of non-
neoplastic, stromal and inflammatory cells [13]. In
addition, the availability and/or the quality of the
specimens suitable for molecular evaluations could be
scare, since formalin-fixed paraffin-embedded (FFPE)
samples from small biopsies or cytology specimens
could represent the only available material. [14].
Moreover, in recent years, non-invasive approaches
(collectively called “liquid biopsy”) have been devel-
oped to identify the molecular profile of tumor
circulating cells (TCCs) or circulating tumor DNA
(ctDNA) [15–18] and therefore very sensitive detec-
tion methods are required. For all of these reasons, it
Fig. 1 Simplified schema of the most frequently altered signaling pathways in NSCLC. Blue and green ovals indicate the proteins commonly
activated in ADC and SSC, respectively. Druggable TKIs and approved targeted agents are specified
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is critical to use reliable and sensitive diagnostic
methods capable of simultaneously detecting a wide
range of mutations also in poor quality samples.
Different molecular approaches, such as Sanger
sequencing, real-time PCR, pyrosequencing, MALDI-
TOF mass spectrometry (MS) and next-generation se-
quencing (NGS) are currently available [19–22].
Among them, Sanger sequencing is the less sensitive
(at least 20% of mutant alleles); MS is considered a
robust approach for the genotyping of known muta-
tions, able to combine the advantages of multiplexing,
high sensitivity, and specificity with rapid turnaround,
easy sample handling, and cost-effectiveness [19, 20].
Finally, although NGS is a very robust approach with
the highest sensitivity [23], it is less affordable than
the other approaches and poses several additional
challenges, including validation and data handling for
diagnostic purposes. Besides, to preserve the cost per
test and avoid wasting resources, a consistent number
of cases should be simultaneously analyzed.
Using the MS genotyping approach, we tested a cohort
of 92 NSCLCs, investigating a wide spectrum of actionable
mutations currently targeted by specific therapies or for
which clinical trials are ongoing. Our aim was to verify the
performance and sensitivity of the method using low levels
of tumor DNA. Finally, we evaluated the performance of
MS on plasma DNA from 13 lung cancer patients with
EGFR- or KRAS-mutated tumors.
Methods
Patients and tumor specimens
The study group included 92 NSCLC cases collected for
clinical purposes at the Fondazione IRCCS Ca′ Granda,
Ospedale Maggiore Policlinico di Milano (Italy), between
September 2011 and December 2013. The molecular
evaluation of all cases at the time of diagnosis was carried
out by pyrosequencing using Ce-IVD kits (EGFR TKi
response (sensitivity), EGFR TKI response (resistance),
Anti-EGFR MoAb response KRAS status, Anti-EGFR
MoAb response BRAF status - Diatech Pharmacogenetics
s.r.l., Jesi, Italy). We included in the study the NSCLC
cases for which the biologic material was available. The
study was approved by the Institutional Ethic Commit-
tee (Fondazione IRCCS Ca′ Granda, Ospedale Maggiore
Policlinico di Milano N°526/2015).
For ctDNA analysis, peripheral blood samples were
collected from additional 13 lung cancer patients at the
time of biopsy/surgical procedures after informed con-
sent. The inclusion criteria were the presence of ADC,
the availability of tumor specimens and the positivity for
EGFR or KRAS mutations.
Hematoxylin/eosin-stained sections (H&E) from FFPE
tissues were evaluated by a pathologist for routine
histopathologic classification and identification of the
tumor component. Diagnosis was performed according
to the criteria of the 2015 WHO classification for lung
tumors [24].
Ninety-two NSCLC specimens of primary or meta-
static lung tumors, including 28 cytological and 64
histological samples, were classified as follows: 78
ADCs, 11 SCCs, and 3 NSCLCs, not classified more
precisely because of the paucity of biological speci-
mens (Table 1). All thirteen cases selected for ctDNA
profiling were ADCs.
DNAs from NSCLC FFPE samples were obtained
using the BiOstic FFPE Tissue DNA Isolation Kit (MO
BIO Laboratories Inc., Carlsbad, CA, USA) and quanti-
fied using a NanoDrop 1000 UV spectrophotometer,
software version 3.7.1 (Thermo Fisher Scientific Inc.,
Waltham, MA, USA).
ctDNA was extracted with the Helix Circulating
Nucleic Acid kit (Diatech Pharmacogenetics, Jesi, Italy)
from 3 to 5 ml of plasma obtained from about 10 ml of
peripheral blood, collected in EDTA tubes. Following
the manufacturer’s instructions, ctDNA was finally
eluted in 30 μl and not subsequently quantified.
MS genotyping assay
A panel of actionable loci was selected based on the
Catalogue of Somatic Mutations in Cancer (COSMIC;
http://cancer.sanger.ac.uk/cosmic), My Cancer Genome
(https://www.mycancergenome.org), and relevant litera-
ture [11]. The panel comprised 158 variations affecting
commonly mutated genes in NSCLC: EGFR, KRAS,
BRAF, ALK, PIK3CA, ERBB2, DDR2, AKT, and MEK1.
Reference DNA sequences were retrieved from Ensembl
Genome Browser (http://www.ensembl.org/index.html).
Tissue DNAs and ctDNAs were genotyped using the
single-base extension technique on a MassARRAY
analyzer 4. Amplification and extension primers were
designed using the Assay Designer Suite v.1.0 (Agena
Bioscience, Hamburg, Germany). Amplification primers
were designed with a 10mer tag sequence (lower cases)
at 5′-end, to avoid their masses overlapping the range of
detection of the MS assay. Primers sequences are avail-
able in Additional file 1: Table 1.
The MS panel consists of 48 assays multiplexed in
eight wells, testing 158 mutations including base
Table 1 Tumor specimens and classification of the 92 NSCLCs
cohort
Number of cases ADC SSC NSC
Total 78 11 3
Histological specimens 57 7 0
Cytological specimens 21 4 3
Primary tumors 64 8 3
Metastases 14 3 0
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substitutions, deletions, and insertions. A complete de-
scription of the mutations is provided in Additional file 2:
Table 2. For PCR, SAP (shrimp alkaline phosphatase),
and extension reactions, the Complete iPLEX Pro
Genotyping Reagent Set (Agena Bioscience) was used.
Amplification products were processed using Spectro-
CHIP II Arrays and Clean Resin Kit and the MassAR-
RAY Nanodispenser (Agena Bioscience). Analyses were
performed using the MassARRAY Typer 4.0 software
(Agena Bioscience).
Depending on the abundance of each sample, the
amount of DNA from FFPE specimens, used as
template, was 10–40 ng per well.
MS assay sensitivity
The analytical sensitivity of the MS assay was deter-
mined by verifying the lowest detectable frequency of a
mutated allele using commercial reference standards
HORIZON (Cambridge, UK) for the following muta-
tions: EGFR G719A, T790 M and L861Q, KRAS Q61L,
and BRAF V600E. The standards were heterozygous for
the mutations, and thus contained the mutated alleles at
50% frequency. Serial dilutions containing 10%, 5%, and
2.5% of the mutated alleles were obtained by mixing
standard samples with wild-type DNA from peripheral
blood lymphocytes (PBLs). PCRs were performed using
50 ng of DNA from each dilution.
To determine the minimum amount of DNA needed
to detect a mutation present at a low allelic frequency,
we used decreasing amounts of DNA (20 ng, 10 ng and
5 ng) from four tumor samples harboring the following
mutations at specific percentages: 30% KRAS G12C, 20%
KRAS G12C, 10% EGFR L858R, and 9% PIK3CA
H1047R. These percentages had been assessed pre-
viously using 40 ng of template DNA.
ctDNA genotyping assay
The presence of mutations in ctDNAs was verified using
our MS analysis, testing only the assay specific for the
mutation previously identified in the tumor sample. To
compare MS with another sensitive method, we per-
formed RT-PCR using the commercial IVD-CE kits Easy
EGFR and Easy KRAS (Diatech Pharmacogenetics, Jesi,
Italy) on Rotor-Gene (Qiagen, Hilden, Germany), follow-
ing the manufacturer’s instructions. RT-PCR results were
analyzed and reported as ΔCt values (Ct sample – Ct
wild-type control).
Notably, the amount of the ctDNA requested by RT-
PCR and MS was 5 and 2 μl, respectively.
Results
Tumor genotyping
We tested 158 actionable mutations comprising base
substitutions, insertions, and deletions of the EGFR,
KRAS, BRAF, ALK, PIK3CA, ERBB2, DDR2, AKT, and
MEK1 genes (Additional file 2: Table 2) in 92 NCSLCs
and in plasma samples from 13 additional NSCLC
patients with known somatic mutations. The mutation
profiling of all cases is detailed in Additional file 3:
Table 3. The overall data from the 92 NCSLCs revealed
that 49 (53.3%) harbored mutations in at least at one
gene. In ADCs, we identified mutations in EGFR
(15.4%), KRAS (37.2%), BRAF (1.3%), ERBB2 (3.8%), and
AKT (2.6%), whereas SCCs exclusively harbored PIK3CA
mutations (27.3%). Mutations of ALK, DDR2, and MEK1
were never detected (Table 2). EGFR primarily contained
in-frame deletions in exon 19 (6 out of 12 EGFR
mutated cases). The T790 M and L858R mutations, con-
comitantly detected in two cases, were the only EGFR
variants found simultaneously in the same tumor sample
(Additional file 3: Table 3).
KRAS was predominantly mutated at codon 12, exon 2
(25 out of 30 KRAS mutated cases) (Additional file 3:
Table 3).
Only KRAS variants were found concomitant with
other mutated genes: AKT and ERBB2, in one case
respectively (Additional file 3: Table 3).
Out of the three unclassified NSCLCs, one had KRAS
G12A mutation (Additional file 3: Table 3), suggesting
that it was ADCs since KRAS is most frequently mutated
in this tumor subtype.
To evaluate the correlation between the mutated al-
leles percentages detected by MS and the amount of
tumor cells at the histopathological evaluation, in two
representative mutated ADCs we compared the stained
slides with the corresponding MS spectra. As displayed
in Additional file 4: Fig. 1, the percentages of mutated al-
leles are not strictly related to the amount of cancer cells
in the samples. Indeed, in the first sample (left), more
than 70% of cells are neoplastic, but only a subset of
them (23% of the alleles) harbors the EGFR L858R
mutation; conversely, in the second ADC (right), the
percentage of mutated allele (49%) indicates that about
Table 2 Mutations found in 92 NSCLC FFPE samples
Classification Total cases Mutated cases EGFR KRAS BRAF ALK PIK3CA ERBB2 DDR2 AKT MEK1
ADC 78 45 (57.7%) 12 (15.4%) 29 (37.2%) 1 (1.3%) – – 3 (3.8%) – 2 (2.6%) –
SCC 11 3 (27.3%) – – – – 3 (27.3%) – – – –
NSCLC 3 1 (33.3%) – 1 (33.3%) – – – – – – –
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all tumor cells in the sample (tumor content >70%) have
the KRAS G12D mutation.
Genotyping sensitivity
The MS sensitivity was assessed evaluating four common
mutations in NSCLC, for which standard commercial
references were available. Using 50 ng of HORIZON refer-
ence standard DNA (RSs, HORIZON) containing the mu-
tations EGFR G719A, EGFR L861Q, EGFR T790 M,
KRAS Q61L, and BRAF V600E in serial dilutions (50%,
10%, 5%, and 2.5%), we found that the sensitivity of MS
assays varied depending on the specific mutation tested.
For EGFR G719A and T790 M, the sensitivity of the as-
says was 2.5%, whereas it was 10% for EGFR L861Q,
KRAS Q61L, and BRAF V600E (Table 3). These data
suggest that MS can detect a mutation with frequency
lower than 10%, and that the sensitivity depends on the
specific mutation.
In addition, we tested the performance of MS using
decreasing amounts of DNA (20 ng, 10 ng, and 5 ng)
from four tumor samples harboring mutations at various
allelic frequencies (previously identified using 40 ng of
DNA). When the frequency of the mutated allele was
lower than 10%, the amount of the template DNA influ-
enced the efficiency of detection (Table 4, Fig. 2). Indeed,
in cases with KRAS G12C and EGFR L858R at 30%,
20%, and 10% allelic frequencies, the mutations could be
detected irrespective of the amount of DNA (Table 4,
Fig. 2). In these cases, the frequency of the mutated
alleles remained stable. Conversely, in the H1047R
PIK3CA sample, with an allelic frequency < 10% (mean
value based on triplicate runs: 8% ± 1), the mutated
allele could be clearly identified by analyzing 20 ng of
DNA, whereas, at lower DNA quantities, the results
were uncertain because the signal corresponding to the
mass of the mutated analyte was insufficient for a
positive call (Table 4, Fig. 2).
These overall data suggest that the sensitivity of MS
for detection of point mutation at low levels of mosai-
cism should be tested for each assay, and that low levels
of DNA amounts could affect the recognition of muta-
tions present at low allelic frequencies.
ctDNA molecular profiling
During the routine molecular evaluation of additional
ADCs, we selected thirteen cases harboring mutations of
EGFR or KRAS and analyzed the corresponding ctDNA
taken from plasma at the time of biopsy/surgery. Of the
thirteen mutations identified in tumor DNA, five
(Table 5: cases 1–5) were also detected in plasma DNA
by real-time PCR, and four of them (Table 5: cases 1–4)
were also detected by MS.
In general, the lower detection of mutations in plasma
compared to FFPE samples, could be due to the sensiti-
vity limit of the methods and/or to the tumor features
(grade, dimension, vascularization, and tissue necrosis),
which can affect the amount of tumor DNA released
into the bloodstream [25].
The discrepancies between the two approaches were
probably not related to the frequencies of mutated
alleles in a tumor sample. The percentages of tumor mu-
tated alleles of cases 1–4 were indeed comparable to
those of cases 5–13, that were not detected in the
plasma (t-test p = 0.06) (Table 5), suggesting that the ra-
tio of the mutated alleles in the tumor specimens does
not impact their detection by MS assay in plasma sam-
ples. The difference in detection rate, between ctDNA
and FFPE DNA, could be due to the intrinsic heterogen-
eity of tumor samples, which could in turn be related to
the different amounts of ctDNA released [26].
In plasma samples the range of the mutated alleles
frequency detected by MS was 5–19%. RT-PCR does not
allow the alleles percentages, a data that could have a
clinical significance in monitoring patients.
Discussion
A large number of proteins activated in cancer and
involved in the intracellular signaling pathways have
been investigated as approved or potential targets for
biological inhibitors. These discoveries led to a signifi-
cant increase in molecular testing on tumor samples.
Consequently, it becomes crucial to select a robust
diagnostic method capable of identifying a wide
spectrum of mutations in low-quality samples and in
Table 3 MS assay sensitivity tested with reference standard
DNA using decreasing percentages of mutated alleles
Percentages of the mutated allele
Reference standard 50% 10% 5% 2.5%
EGFR G719A (c.2156 G > C) D D D D
EGFR L861Q (c.1582 T > A) D D ND ND
EGFR T790 M (c.2369C > T) D D D D
KRAS Q61L (c.182 A > T) D D ND ND
BRAF V600E (c. 1799 T > A) D D ND ND
D: detected. ND: not detected
Table 4 MS assay sensitivity considering various percentages of
mutated alleles with serially diluted DNAs from three FFPE
sample cases
Template DNA amount (ng) KRAS G12C EGFR L858R PIK3CA H1047R
40 30% 20% 10% 9%
20 D D D D
10 D D D ND
5 D D D ND
D: detected. ND: not detected
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a cost-effective manner. We investigated whether MS
would be reliable for this purpose, considering several
challenges of tumor genotyping: the frequent paucity
of available biological material, the low yield of DNA
from FFPE specimens or liquid biopsy, and tumor
heterogeneity, which is associated with variable
frequencies of somatic mosaicism.
We found that mutations at 10% frequency could
always be detected using our multiplexed genotyping
panel, which covers 158 mutations in six genes. How-
ever, we confirmed that the sensitivity of MS depended
on the specific assay, and genetic alterations could also
be detected when the mutated allele frequency is very
low, e.g., 5% or 2.5% [19, 20]. On this basis, assuming
that mutations are heterozygous, a 10% mutated allele
frequency corresponds to 20% of cells carrying the
mutation [27]. In turn, this implies that a minimum of
20% of tumor cells in a tissue specimen should be re-
quired to detect mutations at 10%. However, considering
the tumor heterogeneity, it is also possible that a target
mutation could be present only in a subset of cancer
cells, and thus identifiable by MS, depending on MS
performance for each mutation and the DNA quality.
Another crucial issue is the minimum amount of DNA
needed for analysis. Frequently, the available amount of
DNA is limited by the small sizes of biopsies or cytology
Fig. 2 Spectrograms, mass (x-axis) versus intensity (y-axis) from two histological samples (a, b) containing EGFR and PIK3CA mutations,
respectively, at specific percentages of the mutated alleles (in brackets). Arrows indicate the mass peaks of the mutated alleles, using the
specified decreasing amounts of DNA. The mass peaks of the wild-type alleles are also shown (WT). Using 5 ng of tumor DNA, the peak corre-
sponding to the mutations was insufficient for a positive call for PIK3CA (b), but sufficient for EGFR
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specimens. We observed a relationship between the fre-
quency of a mutated allele in the sample and the amount
of DNA required for detection. This is partially in
contrast to the findings of Magliacane et al. (2015), who
reported that mutations could be detected even using
very small amounts of DNA (1 ng per reaction) [28]. In
particular, we observed that, in the presence of highly
represented mutations (about 20%), only a very small
amount of DNA (about 5 ng) was sufficient for the de-
tection. By contrast, the quantity of DNA is crucial when
identifying mutations with a frequency lower than 10%.
Mutations represented at 10% and 30% were detected in
all cases, but, when the mutated allele frequency was
lower than 10%, the amount of template DNA influ-
enced the performance of the MS analysis.
Taken together, these results showed that, to define
the robustness of molecular profiling using MS, it is
necessary to set the sensitivity of the method for each
mutation to be investigated.
The validity of the mutation detection by MS was con-
firmed by comparison with the results reported in the
literature: KRAS is the most frequently mutated gene in
ADCs (37.2%), followed by EGFR (14.4%), whereas
PIK3CA is frequently mutated in SCCs (27.3%) [10].
Three NSCLC cases were not further classified be-
cause of the paucity of specimens. Our molecular results
identified the KRAS G12A mutation in one of them,
suggesting that it could be classified as ADCs. This case
confirms the importance of molecular profiling evalu-
ation in lung cancer to complete the histopathological
diagnosis, as already indicated for brain tumors [29].
In summary, MS allows the genotyping of several sam-
ples simultaneously by screening many known mutations
in a single and cost effective test. It has high sensitivity,
an important feature when a minority of mutant alleles
must be distinguished from abundant wild-type alleles,
and also allows mutations to be detected from a small
amount of low-quality DNA, such as that typically ob-
tained from poor-quality tissue specimens. Therefore,
our experience emphasizes that it may not be appropri-
ate to decline to perform molecular diagnosis on tissue
specimens with a tumor component lower than 20%, or
on poor biological materials.
Regarding the ctDNA evaluation, we observed con-
cordant mutation detection between tumor tissue and
plasma in four out of thirteen cases using MS,
whereas, when using real-time PCR, we detected the
tumor mutation in an additional case. The low sensi-
tivity of both methods could be due to the low level
of the mutated allele in the bloodstream or to tumor
heterogeneity, although the small number of analyzed
cases prevents us from drawing definitive conclusions.
MS seems to be quite less sensitive than real-time
PCR; however, MS has the advantage to screen panels
of variations simultaneously. Our preliminary data
suggest that, although in some cases analysis of
ctDNA alone can be insufficient, MS has the potential
to analyze liquid biopsy and monitor patients during
treatment. Moreover, MS allows the estimation of
alleles percentages, a data that could have a clinical
significance in monitoring patients.
Conclusions
Our paper provides important advises for the use of MS
in predictive analyses.
Table 5 Mutation detection in ctDNA by real-time PCR and MS approaches
Patients with EGFR/KRAS
mutated tumors
Mutation in FFPE tumors
(mutated allele percentage)
Mutation detection in ctDNA
by real-time PCR (ΔCt values)
Mutation detection in ctDNA by
MS (mutated allele percentage)
1 EGFR L858R (56%) D (2.55) EGFR L858R (7%)
2 EGFR E746_A750delELREA (27%) D (1.44) EGFR E746_A750delELREA (5%)
3 EGFR E746_A750delELREA (60%) D (3.66) EGFR E746_A750delELREA (12%)
4 EGFR E746_A750delELREA (55%) D (3) EGFR E746_A750delELREA (19%)
5 EGFR E746_E750delELREA (50%) D (4.02) ND
6 EGFR E746_A750delELREA (30%) ND (12.61) ND
7 EGFR E746_A750delELREA (30%) ND (14.03) ND
8 EGFR L858R (18%) ND (18.99) ND
9 KRAS G12 V (50%) ND (27.23) ND
10 KRAS G12 V (41%) ND (18.78) ND
11 KRAS G12C (17%) ND (19.63) ND
12 KRAS G12 V (33%) ND (27.23) ND
13 KRAS G12C (20%) ND (16.95) ND
D: detected. ND: not detected
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By analyzing 158 sequence alterations of the most
frequently NSCLCs mutated genes in 92 tumor speci-
mens, we confirmed that the method is able to detect
mutated alleles present at 2,5% in the tumor speci-
mens, and that the sensitivity can vary, depending on
the mutation analyzed [19].
Interestingly, we noticed that the amount of DNA
could affect the analysis. Specifically, when the
mutation is present in more than 10% of alleles it is
detectable even using low DNA amount (5 ng), but
when the mutated alleles are less than 10%, the muta-
tion detection can be compromised when using as
low as 10 ng of DNA.
Finally, a proof-of concept investigation on liquid
biopsy testing suggests that MS can be a reliable
approach for this purpose even though it needs to be
improved.
MS is a powerful and high throughput method for
detecting known mutations, and allows to genotype
scarce component of tumor cells in the tissue speci-
men, this has an important impact on patient clinical
management.
Additional files
Additional file 1: Table S1. Amplification and extension primer
sequences for MS panel. (DOCX 16 kb)
Additional file 2: Table S2. List of alterations (base substitutions,
deletions, and insertions) included in the MS panel. On the left,
mutations not distinguishable from one another are indicated by the
same number. (DOCX 30 kb)
Additional file 3: Table S3. Molecular profile of NSCLC mutated cases.
For each detected mutation, the number of positive cases and the
diagnosis are reported. (DOCX 14 kb)
Additional file 4: Figure 1. H&E staining of two ADCs cases and the
corresponding mutation MS spectra. A H&E staining of two ADCs cases.
5X zoom of the rectangular area is shown. The percentage of cancer cells
is higher than 70% in both samples. B MS spectra of the two ADCs cases
harboring EGFR L858R and KRAS G12D mutations, respectively. The
mutated alleles are pointed out by black arrows and the corresponding
percentages are reported in each spectrum. (TIFF 26330 kb)
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